Non-inflammatory disorder of vagina, unspecified
Conditions
Interventions
Topical estrogen therapy group - patients will be advised to apply 1g of
vaginal cream (estriol 1mg / g) every night for 20 days and then weekly application for 4 consecutive months (20 patients)
Las
Drug
Procedure/surgery
Sponsors
Universidade Federal de São Paulo
Universidade Federal de São Paulo
Eligibility
Sex/Gender
Female
Age
50 Years to 60 Years
Inclusion criteria
Inclusion criteria: Age over 50 years;no menstruation 12 months ago; presence of symptoms resulting from vulvovaginal atrophy, a conventional Pap smear examination of Frost consistent with atrophic status and who have not undergone hormone replacement in last 3 months
Exclusion criteria
Exclusion criteria: urogenital infection or inflammation of character acute or recurrent;pre-neoplastic lesions;pelvic prolapses; pregnant women; immunosuppressive patients, severe chronic diseases; previous pelvic surgery;use of hormone therapy for less than 3 months;previous pelvic radiotherapy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| - increased cell proliferation through the evaluation of the FROST index and the measurement of thickness (Breslow's rule will be used) in the group of women undergoing lasertapia ;- increased vascular proliferation (through the evaluation of VEGF and Ki 67 reagents) in the group of women undergoing lasertapia | — |
Secondary
| Measure | Time frame |
|---|---|
| - significant increase in cell and vascular proliferation in the group of women undergoing topical estrogen therapy | — |
Countries
Brazil
Contacts
Public ContactPaula Pallone Dutra
Universidade Federal de São Paulo
Outcome results
None listed